Source: The Pharmacogenomics Journal. Unidades: EERP, FMRP
Subjects: INIBIDORES DE ENZIMAS, METALOPROTEINASES, POLIMORFISMO, HIPERTENSÃO NA GRAVIDEZ
ABNT
LUIZON, M. R. et al. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. The Pharmacogenomics Journal, v. 14, n. 6, p. 535-541, 2014Tradução . . Disponível em: https://doi.org/10.1038/tpj.2014.26. Acesso em: 04 out. 2024.APA
Luizon, M. R., Palei, A. C. T., Sandrim, V. C., Amaral, L. M., Machado, J. S. R., Lacchini, R., et al. (2014). Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. The Pharmacogenomics Journal, 14( 6), 535-541. doi:10.1038/tpj.2014.26NLM
Luizon MR, Palei ACT, Sandrim VC, Amaral LM, Machado JSR, Lacchini R, Cavalli R de C, Duarte G, Tanus-Santos JE. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy [Internet]. The Pharmacogenomics Journal. 2014 ; 14( 6): 535-541.[citado 2024 out. 04 ] Available from: https://doi.org/10.1038/tpj.2014.26Vancouver
Luizon MR, Palei ACT, Sandrim VC, Amaral LM, Machado JSR, Lacchini R, Cavalli R de C, Duarte G, Tanus-Santos JE. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy [Internet]. The Pharmacogenomics Journal. 2014 ; 14( 6): 535-541.[citado 2024 out. 04 ] Available from: https://doi.org/10.1038/tpj.2014.26